AstraZeneca initiates phase III clinical development of fostamatinib for the treatment of rheumatoid arthritis

Wednesday, 29 September 2010 AstraZeneca today announced the enrollment of the first patient in the phase III clinical development programme for fostamatinib, a novel oral syk inhibitor. The phase III programme, called OSKIRA (Oral Syk Inhibition in Rheumatoid Arthritis), is designed to investigate fostamatinib as a treatment for rheumatoid arthritis (RA) in patients with an inadequate response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX). The OSKIRA clinical trial programme will include three pivotal phase III studies assessing the efficacy and tolerability of fostamatinib; two 12-month studies examining the effect of fostamatinib on patients responding inadequately to DMARDs including MTX, and a six-month study assessing the effect of fostamatinib on patients who have previously responded inadequately to anti-TNF therapy. The fostamatinib programme will also include long-term safety extension studies involving more than 2,000 of the patients recruited during the course of the phase II and III programmes. “We are delighted that the OSKIRA clinical trial programme for fostamatinib has begun,” said Anders Ekblom, AstraZeneca’s Executive Vice President of Global Medicines Development. “Patients with rheumatoid arthritis currently have limited treatment options after they stop responding adequately to DMARDs or anti-TNF therapy, and we are hopeful that fostamatinib may represent a novel alternative for patients to help manage their condition beyond this stage.” All three pivotal studies start with a six-month double-blind, randomised, placebo-controlled period, and the two 12-month studies also include a six-month active-extension period. The primary outcome measures across the three studies include ACR 20* response rate at six months, and one of the 12-month studies also includes the change in structural progression at six months as a primary endpoint. Two dose regimens of fostamatinib will be evaluated in the phase III programme; a 100mg twice daily regimen and a second regimen investigating 100mg twice daily for four weeks followed by a maintenance dose of 150mg once daily. Fostamatinib, previously referred to as R788, is the first oral syk inhibitor in development, and as such, represents a novel therapeutic approach for RA. A phase II programme has recently been completed, which demonstrated positive results in patients with rheumatoid arthritis who were responding inadequately to ongoing treatment with MTX. This six-month study data, known as TASKi2, was recently published in the online edition of the New England Journal of Medicine on September 22, 2010. The first anticipated regulatory filings based on the OSKIRA programme are planned for 2013. Fostamatinib was in-licensed by AstraZeneca from Rigel Pharmaceuticals, Inc. in February 2010. NOTES TO EDITORS: About Fostamatinib Fostamatinib (previously referred to as R788), is the first oral syk inhibitor in development as a novel therapeutic approach for RA. It is thought to reversibly block signalling in multiple cell types involved in inflammation and tissue degradation in RA. In February 2010, AstraZeneca and Rigel Pharmaceuticals announced a worldwide license agreement whereby AstraZeneca will develop and commercialise fostamatinib. About RA Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease, which causes damage to the joints and other organs, affecting approximately 1 in 100 people. It is a major cause of disability and is also associated with reduced life expectancy, especially if not adequately treated. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com . Contacts: Media enquiries: Neil McCrae +44 20 7604 8236 (24 hours) Chris Sampson +44 20 7604 8031 (24 hours) Sarah Lindgreen +44 20 7604 8033 (24 hours) Abigail Baron +44 20 7604 8034 (24 hours) Media Enquiries US: Tracy Knudsen + 32 472 900 803 Investor Enquiries UK: Jonathan Hunt +44 20 7604 8122 mob: +44 7775 704032 Karl Hård +44 20 7604 8123 mob: +44 7789 654364 Clive Morris +44 20 7604 8124 mob: +44 7710 031012 Investor Enquiries US: Ed Seage +1 302 886 4065 mob: +1 302 373 1361 Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043 tags Corporate and financial AstraZeneca Websites This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network. Veeva ID: Z4-8411 Date of next review: August 2020 Resources All resources Open Innovation Externally sponsored scientific research MedImmune US prescription assistance programmes Global clinical trials information Medicines Report a possible side effect Pearl Therapeutics Quick links Media Investor Relations Partnering Careers Sustainability Modern Slavery Statement Supplier information Social Media Facebook LinkedIn Twitter Glassdoor utility links Legal notice and Terms of Use Privacy notice Cookie policy Site map Contact us © AstraZeneca 2019 You are now leaving AstraZeneca.com You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Cancel Continue ? Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes. I disagree I agree ? ?

The release as fetched from its publisher. astrazeneca.com ↗